Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction

Abstract Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial lung disease (ILD), driving its mortality. Specific biomarkers associated with the progression of this lung disease are highly needed. We aimed to identify specific biomarkers of SSc-ILD...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julien Guiot, Makon-Sébastien Njock, Béatrice André, Fanny Gester, Monique Henket, Dominique de Seny, Catherine Moermans, Michel G. Malaise, Renaud Louis
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/332d152eea1a43e2b6806c3da08770b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:332d152eea1a43e2b6806c3da08770b0
record_format	dspace
spelling	oai:doaj.org-article:332d152eea1a43e2b6806c3da08770b02021-12-02T16:53:18ZSerum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction10.1038/s41598-021-90333-02045-2322https://doaj.org/article/332d152eea1a43e2b6806c3da08770b02021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90333-0https://doaj.org/toc/2045-2322Abstract Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial lung disease (ILD), driving its mortality. Specific biomarkers associated with the progression of this lung disease are highly needed. We aimed to identify specific biomarkers of SSc-ILD to predict the evolution of the disease. For this, we compared prospectively serum levels of several biomarkers associated with lung fibrosis in SSc patients (n = 102), among which SSc-no ILD (n = 63) and SSc-ILD (n = 39), compared to healthy subjects (HS) (n = 39). We also performed a longitudinal study in a subgroup of 28 patients analyzing biomarkers variations and pulmonary function tests over a period of 2 years. Serum level of IGFBP-2 was significantly increased in SSc patients compared to HS, and negatively correlated with pulmonary function (assessed by carbon monoxide transfer coefficient (KCO)) (r = − 0.29, p < 0.01). Two-year longitudinal analysis in a subgroup of 28 SSc patients determined that IGFBP-2 variation was positively correlated with KCO at 2-year follow-up (r = 0.6, p < 0.001). SSc patients with a lower variation of IGFBP-2 (less than 22%) presented significant deterioration of pulmonary function at 2-year follow-up (p < 0.01). ROC curve analysis enabled us to identify that baseline IGFBP-2 > 105 ng/ml was associated with a poor outcome (KCO < 70% predicted) at 2-year follow-up (AUC = 0.75, p < 0.05). We showed for the first time that serum levels of IGFBP-2 might be a prognostic factor of the development of SSc-ILD.Julien GuiotMakon-Sébastien NjockBéatrice AndréFanny GesterMonique HenketDominique de SenyCatherine MoermansMichel G. MalaiseRenaud LouisNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Julien Guiot Makon-Sébastien Njock Béatrice André Fanny Gester Monique Henket Dominique de Seny Catherine Moermans Michel G. Malaise Renaud Louis Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
description	Abstract Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial lung disease (ILD), driving its mortality. Specific biomarkers associated with the progression of this lung disease are highly needed. We aimed to identify specific biomarkers of SSc-ILD to predict the evolution of the disease. For this, we compared prospectively serum levels of several biomarkers associated with lung fibrosis in SSc patients (n = 102), among which SSc-no ILD (n = 63) and SSc-ILD (n = 39), compared to healthy subjects (HS) (n = 39). We also performed a longitudinal study in a subgroup of 28 patients analyzing biomarkers variations and pulmonary function tests over a period of 2 years. Serum level of IGFBP-2 was significantly increased in SSc patients compared to HS, and negatively correlated with pulmonary function (assessed by carbon monoxide transfer coefficient (KCO)) (r = − 0.29, p < 0.01). Two-year longitudinal analysis in a subgroup of 28 SSc patients determined that IGFBP-2 variation was positively correlated with KCO at 2-year follow-up (r = 0.6, p < 0.001). SSc patients with a lower variation of IGFBP-2 (less than 22%) presented significant deterioration of pulmonary function at 2-year follow-up (p < 0.01). ROC curve analysis enabled us to identify that baseline IGFBP-2 > 105 ng/ml was associated with a poor outcome (KCO < 70% predicted) at 2-year follow-up (AUC = 0.75, p < 0.05). We showed for the first time that serum levels of IGFBP-2 might be a prognostic factor of the development of SSc-ILD.
format	article
author	Julien Guiot Makon-Sébastien Njock Béatrice André Fanny Gester Monique Henket Dominique de Seny Catherine Moermans Michel G. Malaise Renaud Louis
author_facet	Julien Guiot Makon-Sébastien Njock Béatrice André Fanny Gester Monique Henket Dominique de Seny Catherine Moermans Michel G. Malaise Renaud Louis
author_sort	Julien Guiot
title	Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
title_short	Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
title_full	Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
title_fullStr	Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
title_full_unstemmed	Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
title_sort	serum igfbp-2 in systemic sclerosis as a prognostic factor of lung dysfunction
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/332d152eea1a43e2b6806c3da08770b0
work_keys_str_mv	AT julienguiot serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT makonsebastiennjock serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT beatriceandre serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT fannygester serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT moniquehenket serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT dominiquedeseny serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT catherinemoermans serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT michelgmalaise serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction AT renaudlouis serumigfbp2insystemicsclerosisasaprognosticfactoroflungdysfunction
_version_	1718382849606811648

Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction

Ejemplares similares